Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
PD173955 (PD-173955), a src-selective tyrosine kinase inhibitor, is a novel and potent Bcr-Abl inhibitor with potential anticancer activity. It inhibits Bcr-Abl with an IC50 of 1-2 nM, it also inhibits Src activity with IC50 of 22 nM.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References | |||
Additional Infomation |
PD173955 is a dichlorobenzene, a methyl sulfide, a pyridopyrimidine and an aryl sulfide. It has a role as a tyrosine kinase inhibitor.
|
Molecular Formula |
C21H16CL2N4OS
|
|
---|---|---|
Molecular Weight |
443.35
|
|
Exact Mass |
442.042
|
|
Elemental Analysis |
C, 56.89; H, 3.64; Cl, 15.99; N, 12.64; O, 3.61; S, 7.23
|
|
CAS # |
260415-63-2
|
|
Related CAS # |
|
|
PubChem CID |
447077
|
|
Appearance |
white solid powder
|
|
Density |
1.5±0.1 g/cm3
|
|
Boiling Point |
626.7±65.0 °C at 760 mmHg
|
|
Flash Point |
332.8±34.3 °C
|
|
Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
|
Index of Refraction |
1.725
|
|
LogP |
4.74
|
|
Hydrogen Bond Donor Count |
1
|
|
Hydrogen Bond Acceptor Count |
5
|
|
Rotatable Bond Count |
4
|
|
Heavy Atom Count |
29
|
|
Complexity |
626
|
|
Defined Atom Stereocenter Count |
0
|
|
SMILES |
O=C1C(C2=C(Cl)C=CC=C2Cl)=CC3=CN=C(NC4=CC=CC(SC)=C4)N=C3N1C
|
|
InChi Key |
VAARYSWULJUGST-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C21H16Cl2N4OS/c1-27-19-12(9-15(20(27)28)18-16(22)7-4-8-17(18)23)11-24-21(26-19)25-13-5-3-6-14(10-13)29-2/h3-11H,1-2H3,(H,24,25,26)
|
|
Chemical Name |
6-(2,6-dichlorophenyl)-8-methyl-2-((3-(methylthio)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (2.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2556 mL | 11.2778 mL | 22.5555 mL | |
5 mM | 0.4511 mL | 2.2556 mL | 4.5111 mL | |
10 mM | 0.2256 mL | 1.1278 mL | 2.2556 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
PD173955 inhibits Bcr-Abl-dependent substrate tyrosine phosphorylation in vivo.Cancer Res.2002 Aug 1;62(15):4244-55. td> |
PD173955 induces strong accumulation in G1 phase of the cell cycle. Cancer Res. 2002 Aug 1;62(15):4244-55. td> |
PD173955 and PD166326 selectively inhibit the growth of primary CD34+ CML primitive progenitor cells from a patient with chronic phase CML.Cancer Res.2002 Aug 1;62(15):4244-55. td> |